OBI Pharma, Inc. (4174.TWO)
TWD 55.8
(-10.0%)
TWD 55.8
(-10.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -855.08 Million TWD | 38.87% |
| 2022 | -1.66 Billion TWD | -9.48% |
| 2021 | -1.52 Billion TWD | -21.03% |
| 2020 | -1.25 Billion TWD | 1.36% |
| 2019 | -1.5 Billion TWD | -12.69% |
| 2018 | -1.13 Billion TWD | 13.56% |
| 2017 | -1.3 Billion TWD | -23.26% |
| 2016 | -1.06 Billion TWD | -3.13% |
| 2015 | -906.38 Million TWD | -49.71% |
| 2014 | -687.86 Million TWD | -52.36% |
| 2013 | -451.46 Million TWD | -66.49% |
| 2012 | -235.65 Million TWD | -103.17% |
| 2011 | -91.28 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -491.16 Million TWD | 3.59% |
| 2024 Q1 | -517.26 Million TWD | -13.87% |
| 2024 Q3 | -534.05 Million TWD | -6.13% |
| 2023 Q3 | -556.1 Million TWD | -240.12% |
| 2023 Q4 | -504.16 Million TWD | 9.34% |
| 2023 FY | - TWD | 38.87% |
| 2023 Q1 | -355.27 Million TWD | 41.39% |
| 2023 Q2 | 396.88 Million TWD | 211.71% |
| 2022 FY | - TWD | -9.48% |
| 2022 Q3 | -384.8 Million TWD | -8.31% |
| 2022 Q1 | -320.27 Million TWD | 43.43% |
| 2022 Q2 | -355.28 Million TWD | -10.93% |
| 2022 Q4 | -606.12 Million TWD | -57.51% |
| 2021 Q4 | -566.17 Million TWD | -67.52% |
| 2021 FY | - TWD | -21.03% |
| 2021 Q2 | -411.73 Million TWD | -99.59% |
| 2021 Q3 | -337.97 Million TWD | 17.91% |
| 2021 Q1 | -206.29 Million TWD | 45.17% |
| 2020 Q1 | -276.55 Million TWD | 41.86% |
| 2020 Q3 | -345.99 Million TWD | -33.66% |
| 2020 Q2 | -258.85 Million TWD | 6.4% |
| 2020 FY | - TWD | 1.36% |
| 2020 Q4 | -376.25 Million TWD | -8.75% |
| 2019 Q2 | -329.3 Million TWD | -79.67% |
| 2019 FY | - TWD | -12.69% |
| 2019 Q1 | -183.28 Million TWD | 51.49% |
| 2019 Q3 | -286.79 Million TWD | 12.91% |
| 2019 Q4 | -475.66 Million TWD | -65.85% |
| 2018 Q3 | -392.7 Million TWD | -210.84% |
| 2018 Q1 | -234.69 Million TWD | 30.38% |
| 2018 FY | - TWD | 13.56% |
| 2018 Q4 | -377.79 Million TWD | 3.8% |
| 2018 Q2 | -126.33 Million TWD | 46.17% |
| 2017 FY | - TWD | -23.26% |
| 2017 Q4 | -337.1 Million TWD | -5.85% |
| 2017 Q3 | -318.47 Million TWD | -20.95% |
| 2017 Q2 | -263.32 Million TWD | 32.5% |
| 2017 Q1 | -390.08 Million TWD | -12.3% |
| 2016 FY | - TWD | -3.13% |
| 2016 Q1 | -271.53 Million TWD | -3.19% |
| 2016 Q4 | -347.35 Million TWD | -15.98% |
| 2016 Q2 | -143.59 Million TWD | 47.12% |
| 2016 Q3 | -299.49 Million TWD | -108.57% |
| 2015 Q2 | -176.57 Million TWD | 52.03% |
| 2015 FY | - TWD | -49.71% |
| 2015 Q4 | -263.15 Million TWD | -18.57% |
| 2015 Q3 | -221.94 Million TWD | -25.69% |
| 2015 Q1 | -368.11 Million TWD | -90.99% |
| 2014 Q3 | -153.89 Million TWD | 30.78% |
| 2014 Q2 | -222.33 Million TWD | -86.99% |
| 2014 Q1 | -118.9 Million TWD | 13.55% |
| 2014 FY | - TWD | -52.36% |
| 2014 Q4 | -192.73 Million TWD | -25.24% |
| 2013 Q1 | -107.43 Million TWD | -38.54% |
| 2013 Q2 | -162.93 Million TWD | -51.66% |
| 2013 FY | - TWD | -66.49% |
| 2013 Q3 | -101.19 Million TWD | 37.89% |
| 2013 Q4 | -137.53 Million TWD | -35.91% |
| 2012 Q4 | -77.55 Million TWD | 0.0% |
| 2012 Q3 | -77.55 Million TWD | 0.0% |
| 2012 FY | - TWD | -103.17% |
| 2011 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -46.24 Million TWD | -1749.072% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 393.6 Million TWD | 317.244% |
| Level Biotechnology Inc. | 98.7 Million TWD | 966.312% |
| Sagittarius Life Science Corp | -44.73 Million TWD | -1811.274% |
| NeoCore Technology Co., Ltd. | -72.11 Million TWD | -1085.724% |
| TaiMed Biologics Inc. | -25.23 Million TWD | -3288.757% |
| GlycoNex Incorporation | -126.82 Million TWD | -574.214% |
| VBI | -6.97 Million TWD | -12164.558% |
| GeneReach Biotechnology Corp. | -143.69 Million TWD | -495.069% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 21.81 Million TWD | 4020.61% |
| SynCore Biotechnology Co.,Ltd | -17.72 Million TWD | -4723.903% |
| Genomics BioSci & Tech. Co.,Ltd. | -103.61 Million TWD | -725.252% |
| Visgeneer Inc. | 973 Thousand TWD | 87981.295% |
| Mycenax Biotech Inc. | -339.48 Million TWD | -151.879% |
| Sunmax Biotechnology Co., Ltd. | 936.46 Million TWD | 191.31% |
| G&E Herbal Biotechnology Co., Ltd. | 99.83 Million TWD | 956.481% |
| Neith Corporation | -33.61 Million TWD | -2444.139% |
| Medigen Vaccine Biologics Corporation | -991.09 Million TWD | 13.723% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -1.73 Million TWD | -49127.691% |
| Enimmune corporation | -228.96 Million TWD | -273.46% |
| TaiRx, Inc. | -208.64 Million TWD | -309.826% |
| CHO Pharma, Inc. | -277.73 Million TWD | -207.882% |
| EirGenix Inc. | -664.4 Million TWD | -28.699% |
| BioLASCO Taiwan Co., Ltd. | 73.9 Million TWD | 1257.021% |
| Sunny Pharmtech Inc. | 69.14 Million TWD | 1336.691% |
| Lin BioScience, Inc. | -1.07 Billion TWD | 20.19% |
| BioGend Therapeutics Co., Ltd. | -113.1 Million TWD | -656.003% |
| Feng Chi Biotech Corp. | 34.83 Million TWD | 2554.461% |
| Bio Preventive Medicine Corp. | -62.34 Million TWD | -1271.625% |
| Lukas Biomedical Inc. | -26.3 Million TWD | -3151.274% |
| RBC Bioscience Corporation | 36.54 Million TWD | 2439.686% |
| BiOptic Inc. | 65.03 Million TWD | 1414.747% |
| BRIM Biotechnology, Inc. | -682.46 Million TWD | -25.294% |
| Shine-On BioMedical Co.,Ltd. | -33 Million TWD | -2490.696% |
| Great Novel Therapeutics Biotech & Medicals | -54.91 Million TWD | -1457.106% |
| Syngen Biotech Co.,Ltd. | 433.55 Million TWD | 297.226% |
| Advagene Biopharma Co., Ltd. | -80.07 Million TWD | -967.895% |
| NaviFUS Corp. | -55.79 Million TWD | -1432.548% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -16.59 Million TWD | -5051.735% |
| Sinew Pharma Inc. | -163.63 Million TWD | -422.569% |
| Andros Pharmaceuticals Co.,Ltd | -61.5 Million TWD | -1290.382% |
| Greenyn Biotechnology Co., Ltd | 192.4 Million TWD | 544.426% |
| Lumosa Therapeutics Co., Ltd. | -226.67 Million TWD | -277.225% |
| AP Biosciences Inc | -325.51 Million TWD | -162.688% |
| Medigen Biotechnology Corp. | -1.04 Billion TWD | 18.144% |
| 3D Global Biotech Inc. | -35.84 Million TWD | -2285.44% |
| Pharmosa Biopharm Inc. | 29.13 Million TWD | 3035.41% |
| Intech Biopharm Corporation | -219.58 Million TWD | -289.41% |
| Oneness Biotech Co., Ltd. | -674.22 Million TWD | -26.824% |
| Eusol Biotech Co.,Ltd. | -44.95 Million TWD | -1802.26% |
| TWi Biotechnology, Inc. | -160.85 Million TWD | -431.581% |
| Ever Supreme Bio Technology Co., Ltd | 655.52 Million TWD | 230.443% |
| TCI GENE Inc. | 25.98 Million TWD | 3391.194% |
| MegaPro Biomedical Co., Ltd | -110.63 Million TWD | -672.867% |
| Senhwa Biosciences, Inc. | -283.78 Million TWD | -201.314% |
| Taiwan Bio Therapeutics Co., Ltd | -145.97 Million TWD | -485.795% |
| NatureWise Biotech & Medicals Corporation | 13.85 Million TWD | 6273.899% |
| PharmaEngine, Inc. | 347.3 Million TWD | 346.205% |
| Savior Lifetec Corporation | 219.6 Million TWD | 489.374% |
| TaiGen Biopharmaceuticals Holdings Limited | 172.23 Million TWD | 596.479% |
| Meribank Biotech Co., Ltd | -92.56 Million TWD | -823.787% |
| Acepodia, Inc. | -764.51 Million TWD | -11.846% |
| Caliway Biopharmaceuticals Co., Ltd. | -460.09 Million TWD | -85.852% |